Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14525281 | 0.89 | ALDH1A1 (0.58) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL27740065 | 0.88 | P2RY12 (0.54) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL12768057 | 0.86 | P2RY12 (0.52) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL328468 | 0.86 | KDM4E (0.49) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL3664353 | 0.85 | P2RY12 (0.54) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL12727376 | 0.85 | P2RY12 (0.56) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| Hydrochloric Acid SCHEMBL251791 | 0.84 | KDM4E (0.48) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL27740064 | 0.84 | P2RY12 (0.53) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL8737597 | 0.84 | ALDH1A1 (0.51) | P2RY12ALDH1A1KDM4EHPGDTP53 | |
| SCHEMBL14038322 | 0.83 | ALDH1A1 (0.47) | P2RY12ALDH1A1KDM4EHPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946219-B2 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946219-B2 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2146705-B1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARM INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2586439-A1 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | Portola Pharmaceuticals, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2008137753-A2 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137787-A2 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137809-A2 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL] -5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, IN DIFFERENT CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| WO-2007056219-A2 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056167-A2 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | P2RY4, P2RY6, P2RY13 | P2RY12 19/4885ALDH1A1 925/4885KDM4E 1862/4885 |
| US-20120088736-A1 | [4-(6-HALO-7-Substituted-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS and Forms and Methods Related Thereto | P2RX7, P2RY1, P2RY6 | P2RY12 18/4885ALDH1A1 1579/4885KDM4E 3098/4885 |
| US-20070123547-A1 | [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO | P2RX7, P2RY1, P2RY6 | P2RY12 18/4885ALDH1A1 1579/4885KDM4E 3098/4885 |
| US-20120129876-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | P2RY12 17/4885ALDH1A1 712/4885KDM4E 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.